Lupin Targets US Growth With Complex Generics and Biosimilars

Lupin is sharpening its US growth strategy, betting on complex generics and biosimilars to drive its next phase of expansion in the highly competitive American pharmaceutical market.

The Mumbai-based drugmaker said the US market remains a key focus area as it shifts beyond traditional generics to products that offer higher margins and fewer competitors. The company has been steadily building capabilities in complex formulations, drug-device combinations, and biologics as part of this push.

The US growth strategy centers on developing complex generics such as inhalation products, injectables, and other difficult-to-manufacture medicines. These drugs typically face limited competition because of technical and regulatory barriers, allowing companies to command better pricing compared to standard generic medicines.

Also Read: India's Rare Disease Shift Driven by PRIP and PLI Policies

At the same time, Lupin is expanding its presence in biosimilars, which are lower-cost versions of biologic drugs used to treat conditions such as cancer and autoimmune diseases. As patents on several high-value biologic medicines expire globally, biosimilars are expected to open up major opportunities for pharmaceutical companies.

The company leadership highlighted that innovation and specialized products will play a critical role in sustaining US growth strategy over the coming years. Lupin has been investing heavily in research and development to strengthen its pipeline of complex products targeted at the American market.

For decades, the US has been one of Lupin’s largest revenue contributors, but intense price competition in conventional generics has forced companies to move up the value chain. By focusing on complex generics and biosimilars, Lupin aims to improve profitability while expanding its presence in the world’s largest pharmaceutical market.

The strategy reflects a broader shift across the pharmaceutical industry, where companies are increasingly investing in advanced drug development to stay competitive and capture higher-value opportunities in the US healthcare system.